ICER President Discusses Market Outlook Post-Pandemic Amid Drug Pricing Debates

In a recent interview, President of the Institute for Clinical and Economic Reform (ICER) Dr. Steve Pearson spoke about how market access will change as the COVID-19 pandemic slows. Lawmakers at both state and federal levels have expressed increased interest in implementing drug pricing regulation.

“The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.” Read more here.

(Source: Melanie Senior, In Vivo, Informa Pharma Intelligence, 5/12/21)